Mesoblast (MSB) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
10 Nov, 2026Opening remarks and agenda
Vision centered on life-saving cellular therapies, efficient operations, motivated teams, and appropriate shareholder returns.
Financial performance review
FY2026 net revenue was US$115M in RYONCIL’s first full year after U.S. launch; gross profit on sales was US$110M, excluding amortization.
Secured a US$125M five-year non-dilutive credit facility, consolidating and retiring two higher-cost facilities.
Board and executive committee updates
Greg George appointed Interim COO as a search continues for a U.S.-based COO to support manufacturing scale-up and potential rexlemestrocel-L launches.
Eric Rose will focus as CMO on cardiopulmonary programs and step away from Board activities.
Jon Voigtman is expected to join the Board subject to shareholder approval; Bill Burns and Phil Krause will retire, with a search underway for directors with biopharma, manufacturing, and commercial expertise.
Latest events from Mesoblast
- RYONCIL revenue grew 44% as cash spend fell 86%, alongside pivotal trial and FDA progress.MSB
Q1 2027 - $120M revenue, net loss halved, and pipeline progress set up double-digit growth.MSBH2 2026
- RyoncilⓇ net revenue reached US $115M for the year, with strong growth and future momentum expected.MSBQ4 2026 TU
- Ryoncil's commercial success funds a robust pipeline targeting major inflammatory diseases.MSBInvestor presentation
- Ryoncil® revenues hit US$30.3M, cash spend improved, and key clinical milestones were achieved.MSBQ3 2026 TU
- Ryoncil's U.S. launch drove $51.3M H1 revenue and improved net loss to $40.2M.MSBH1 2026
- FDA approves first MSC therapy for pediatric steroid-refractory GVHD, launch imminent.MSBFDA Announcement
- RyoncilⓇ launch drove 191% revenue growth, expanded coverage, and strengthened cash reserves.MSBH2 2025
- FDA approval and $161M raise drive imminent U.S. launch and late-stage pipeline progress.MSBH1 2025